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The AIDS pandemic is spreading unchecked in many
parts of the world. Currently available anti-viral regimens
are plagued by their high cost, by serious side effects in a
significant minority of recipients, and by the increasing
problems of drug-resistant HIV variants. Fortunately,
rapid advances in understanding how HIV-1 enters cells
have lead to the identification of promising new drug tar-
gets and have also suggested new strategies for the genera-
tion of vaccine candidates. The cellular proteins required
for HIV-1 entry have been identified, and structural stud-
 
ies using fragments of the viral envelope protein (Env)
 
1
 
that mediates entry have provided views of Env in two
conformations. However, placing this information in the
appropriate order and kinetic context has not been so
straightforward. A paper published in this issue identifies
the rate limiting step in Env-mediated membrane fusion
and the proximal cause of the membrane fusion reaction
(Melikyan et al., 2000). This study provides an important
insight into why antibodies to several immunodominant
HIV-1 Env epitopes fail to neutralize the virus, informa-
tion that may help in the development of triggered Env
immunogens as vaccine candidates, as well as in the identi-
fication of new inhibitors of virus entry. Two additional
papers provide new knowledge on the structural proper-
ties needed to induce lipid mixing in both viral and cellular
membrane fusion systems, together highlighting the essen-
tial similarities between the viral and cellular systems
(Armstrong et al., 2000; Grote et al., 2000).
The general steps of HIV-1 entry have been elucidated
through direct studies of this virus, as well as of better
characterized viruses like influenza that elicit membrane
fusion using a similar mechanism. HIV-1, like many other
viruses, is surrounded by a lipid membrane from which
protrudes a virally encoded type I membrane protein
(Env). The membrane of the virus and that of the cell
present a formidable physical and energetic barrier be-
tween the viral genome and the cytoplasm of the host cell.
To gain entry, all enveloped viruses mediate a membrane
fusion reaction such that their lipid bilayers become con-
tiguous with that of a cellular membrane (Hernandez et
al., 1996). This process is invariably mediated by a viral fu-
sion protein, such as HIV-1 Env. This homotrimeric pro-
tein is initially synthesized as a single polypeptide precur-
sor that is posttranslationally cleaved into a surface
subunit (gp120) that mediates receptor binding and that
remains noncovalently attached to a transmembrane do-
main subunit (gp41; Wyatt and Sodroski, 1998). Cleavage
liberates the NH
 
2
 
-terminal domain of gp41, a region that
constitutes the protein’s fusion peptide, a stretch of con-
served hydrophobic residues that inserts into the mem-
brane of the host cell during the course of membrane fu-
sion. As such, the cleavage event is a prerequisite for viral
infectivity.
For Env to mediate membrane fusion, it must receive a
signal that causes it to undergo dramatic conformational
rearrangements. For many enveloped viruses, the trigger
that results in the fusion-inducing conformational changes
is acid pH. As first described in 1980 (Helenius et al.,
1980), virus bound to the cell surface is internalized and
delivered to endosomes. There, the acidic environment re-
sults in protonation of acidic residues in the fusion protein,
making the necessary conformational changes possible.
Acid-activated viruses include influenza virus and Semliki
 
Forest virus, which have long served as model systems
for studying virus-membrane fusion. Other viruses, such
as HIV-1, are pH-independent. Here, the information
needed to trigger conformational changes results directly
from receptor binding. The primary receptor for HIV-1 is
the CD4 antigen, to which it binds via the gp120 subunit of
Env. This causes structural alterations in gp120, enabling it
to subsequently bind to a second receptor, termed a core-
ceptor. Coreceptor binding is thought to be the final trig-
ger that leads to membrane fusion. All HIV-1 strains use
one or both of the seven transmembrane domain chemo-
kine receptors, CCR5 and CXCR4, as coreceptors in con-
junction with CD4 for virus entry (Doms et al., 1998). The
differential use of these receptors, coupled with their pat-
terns of expression, largely dictate the cell types that are
susceptible to virus infection in vivo. Individuals who lack
CCR5 due to a deletion in the CCR5 open reading frame
are highly resistant to virus infection, but are immunologi-
cally normal and healthy (Liu et al., 1996; Samson et al.,
1996), indicating that CCR5 antagonists may provide sig-
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nificant protection from virus infection. Indeed, small mol-
ecule antagonists of both CCR5 and CXCR4 have been
developed, and some have entered clinical trials.
The most widely accepted model describing HIV-1 Env-
mediated membrane fusion posits that either CD4 or core-
ceptor binding results in the formation of a coiled-coil in
gp41. This is composed of three NH
 
2
 
-terminal leucine/iso-
leucine zipper regions, one contributed by each subunit of
the Env trimer (Chan et al., 1997; Weissenhorn et al., 1997).
The NH
 
2
 
-terminal fusion peptide is thereby displaced in the
direction of the target membrane into which it can insert
(Fig. 1). As a result, Env transiently becomes an integral
component of two membranes: the viral membrane in
which it is anchored, and the cellular membrane that it has
gaffed. The exterior surface of the coiled-coil contains
grooves into which pack a second, more COOH-terminally
oriented heptad repeat region of gp41. In other words, the
gp41 subunit folds back on itself, forming an exceptionally
stable six-helix bundle (first shown for influenza HA;
Bullough et al., 1994) in which the fusion peptide and trans-
membrane domain of gp41 are now oriented at the same
end of the molecule (Chan et al., 1997; Weissenhorn et al.,
1997). Given the stability of this structure, it is likely that
the six-helix bundle represents the terminal conformation
of a fusogenic Env. Despite considerable differences in pri-
mary sequence, many triggered viral fusion proteins share a
common core structure involving a six-helix bundle that has
the membrane-associated domains at the same end. This in-
dicates that many viral, and perhaps cellular, proteins in-
 
duce membrane fusion by essentially the same mechanism
(Chan and Kim, 1998; Skehel and Wiley, 1998).
Despite all of this knowledge, it has not been clear what
the rate-limiting step of fusion is, whether gp120 remains
associated to gp41 during fusion, what are the exact roles
of the fusion peptide and transmembrane domains, and
whether the stable six-helix bundle is the cause or the re-
sult of membrane fusion. In addition, it is likely that sev-
eral Env trimers are needed for a fusion pore to form, and
multiple receptor binding events are needed per trimer to
activate their fusion potential, resulting in an additional
layer of complexity that is poorly understood.
Melikyan et al. (2000) have used a clever series of inter-
ventional strategies to address several of these lacunae.
Their approach has been to block fusion at discrete stages,
to identify the rate limiting steps in membrane fusion and
the order in which they occur. When cells expressing HIV-1
Env are mixed with cells bearing CD4 and an appropri-
ate coreceptor, cell–cell fusion commences, but only after a
lag phase of 15-20 min. This makes sense in light of how
HIV-1 Env is triggered: unlike acid-activated viruses in
which triggering occurs rapidly and synchronously, so that
all viral envelope proteins are activated within a short pe-
riod, HIV-1 Env triggering is apt to be a much slower and
stochastic process since it is dependent on receptor bind-
ing. Fusion is a highly cooperative process requiring multi-
ple Env proteins and multiple receptor binding events are
needed to activate individual Env trimers, and these prob-
ably occur over a period of time. Hence, we can predict
Figure 1. A, Model for HIV-1 Env membrane fusion. Binding of CD4 to the gp120 subunit of Env induces exposure of a conserved region
in gp120 implicated in coreceptor binding (purple; Rizzuto et al., 1998). In addition, CD4 binding appears to trigger exposure of the triple-
stranded coiled-coil, and presumably exposure of the fusion peptide, although coreceptor binding could increase the efficiency and kinet-
ics of this process. It is not known if the more COOH-terminal helical region in each gp41 subunit (red) interact with each other as drawn,
but it is known that the extodomain of gp41 in general plays an important role in mediating Env oligomerization. Binding to coreceptor
could bring Env in closer proximity to the target membrane, enabling the fusion peptide to insert in the bilayer, or it could impact forma-
tion of the six-helix bundle, the transition to which leads to membrane fusion. Note that in the six-helix bundle, the NH2-terminal helices
form the core of the helix, with the COOH-terminal helices packing in the grooves on the outside of the structure. It is not known if gp120
remains associated with gp41 throughout the fusion process. B, Formation of dead spikes. Binding of soluble CD4 to Env can induce shed-
ding of gp120 from gp41, and can even induce formation of the six-helix bundle. A similar process is likely to occur at the cell surface. Such
modified Env proteins are not fusogenic, but may serve as immunologic decoys. C, Inhibition of fusion by T20. T20 is a small peptide
based on the COOH-terminal helical region in gp41. It binds to the grooves on the outside of the triple-stranded coiled-coil formed by the
NH2-terminal helices. Therefore, it prevents transition to the six-helix bundle and membrane fusion. Only gp41 is depicted for clarity. 
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that the rate of Env triggering will be dependent, in part,
on receptor density, and will perhaps also be influenced by
the Env-receptor affinity. This asynchrony represents a
target of opportunity, because highly conserved regions of
Env that are actual or potential targets for antiviral agents
are transiently exposed during the course of fusion. For ex-
ample, a peptide based on the second helical region in gp41
is a potent inhibitor of HIV-1 membrane fusion, both in
vitro and in vivo (Kilby et al., 1998). This peptide, termed
T20, binds to the exposed grooves on the surface of the tri-
ple stranded coiled-coil, preventing formation of the six-
helix bundle (Fig. 1). Thus, T20 does not target native Env,
but rather a structural intermediate of the fusion process.
An earlier study, confirmed by Melikyan et al. (2000),
showed that HIV-1 Env-mediated fusion is temperature de-
pendent (Frey et al., 1995). When cells expressing Env are
mixed with target cells at 23
 
8
 
C, fusion does not occur, even
after a very long time. Upon warming to 37
 
8
 
C, fusion com-
mences, but without the lag phase that is normally seen with
HIV-1 Env-mediated membrane fusion. Clearly, the steps
responsible for the lag-phase must be able to occur at 23
 
8
 
C.
Therefore, the incubation with receptor-positive cells at
23
 
8
 
C has already allowed Env to achieve an intermediate
state. The key finding provided by Melikyan et al. (2000) is
that the intermediate state is sensitive to T20, indicating
that the triple-stranded coiled coil is accessible under these
conditions. This study also supports the idea that this acti-
vated form of Env can be achieved by binding to CD4
alone: coreceptor binding is not needed (Furuta et al.,
1998). Indeed, it has long been known that the addition of
sCD4 to virions, in the absence of coreceptors, is sufficient
to cause extensive conformational changes in Env, even
leading to the outright dissociation of the gp120 subunits
and exposure of the six-helix bundle form of gp41. This lat-
ter event, however, does not cause membrane fusion to oc-
cur. Indeed, quite the opposite, because fusion is inhibited
by sCD4 under these conditions. What role, then, does
coreceptor-binding play in the fusion process? One possibil-
ity is that the coreceptor association of gp120 accelerates
the transition in Env to its six-helix bundle form, and
thereby ensures that this event occurs at the correct point in
time and space to allow membrane fusion. If the transition
were to take place immediately upon CD4 binding, the fu-
sion peptide may be physically too far from the target cell
membrane to permit its proper insertion. A fusion peptide
left waving in the breeze would be of little use to the virus.
However, the coreceptors are flush with the cell membrane,
so a rapid triggering of the Env transition when gp120 binds
to the coreceptor may ensure that the fusion peptide is close
enough to penetrate the target cell when the gaffing process
is initiated. In fishing terms, CD4-binding may be analogous
to the cocking of the harpoon gun, but coreceptor-binding is
the targeting radar that enables the shooter to pull the trig-
ger only when a fish is actually in sight. Eventually, the
CD4-Env complex will undergo conformational transitions
in the absence of a coreceptor, but this will usually not lead
to a successful insertion of the fusion peptide into the target
cell membrane: the harpoon will miss the fish. In any event,
it appears that the rate-limiting steps in Env-mediated
membrane fusion are related to the conformational changes
induced by receptor binding that result in the formation of
the triple-stranded coiled-coil and/or lateral aggregation of
 
Env-receptor complexes, with the transition to the six-helix
bundle occurring the most quickly.
What role does the six-helix bundle play in membrane
fusion? By modifying membrane curvature through the
addition of exchangeable lipids, Melikyan et al. (2000)
show that formation of the six-helix bundle is coincident
with membrane fusion. Thus, formation of the six-helix
bundle can be considered the proximal cause of the mem-
brane fusion event, and the energy transition involved in
the formation of the six-helix bundle must be sufficient for
a fusion pore to form. As a result, the binding of CD4 and
a coreceptor to HIV-1 Env releases sufficient free energy,
such that membrane fusion can occur. But this energy
must be released and used at the right time for it to drive
membrane fusion; it is not the presence of the six-helix
bundle that allows fusion to occur, it is the formation of
the six-helix bundle that allows fusion to occur. To return
to the gaffing analogy: if one fires a harpoon at a fish, it
must be fired at the right time and place. Merely having a
harpoon dangling in the waves is unlikely to work, since
even fish possess the intelligence not to voluntarily impale
themselves on a static object.
The papers by Armstrong et al. (2000) and Grote et al.
(2000) do not directly address the mechanisms of HIV-1
mediated membrane fusion, but instead focus on the influ-
enza hemagglutinin (HA) protein and the soluble 
 
N
 
-ethyl-
maleimide–sensitive factor attachment protein receptor
(SNARE) fusion system, respectively, the best understood
viral and cellular fusion machines. Like HIV-1 Env, HA is
a homotrimeric protein in which each monomer consists of
a surface (HA1) and transmembrane domain subunit
(HA2). At acid pH, the fusion peptide at the NH
 
2
 
 termi-
nus of the membrane-spanning HA2 subunit is first ex-
posed. Then, through formation of a triple-stranded coiled
coil, it becomes displaced in the direction of the target
membrane into which it inserts (Fig. 2). Several studies
have shown that three to six HA trimers are needed to
form a fusion pore, indicating that lateral aggregation of
HA trimers must occur (Hernandez et al., 1996). Struc-
tural studies have shown that the base of the triple
stranded coiled-coil folds back on itself, forming the now
familiar six-helix bundle (Chen et al., 1999). In doing so,
the fusion peptide and transmembrane domains are
brought in close proximity, which necessarily brings the
target and viral membranes close to each other as well. Fu-
sion mediated by HA may proceed through a hemifusion
intermediate, in which lipids in only the outer leaflets of
each membrane mix (Kemble et al., 1994). As the six-helix
bundle continues to form, bringing the fusion peptide and
transmembrane domains into close proximity, this may re-
sult in disruption of the hemifusion diaphragm and allow a
fusion pore to be made (Fig. 2).
Whereas most studies to date have focused on how the
ectodomains of viral fusion proteins elicit membrane fu-
sion, it has been clear that the transmembrane domain also
plays an important, though poorly defined, role. Substitu-
tion of HA’s TM domain with a GPI-anchor, for example,
does not obviously affect the structure or function of the
influenza HA ectodomain. However, GPI-linked HA elic-
its only hemifusion (Kemble et al., 1994). Under these
conditions, fusion pores either do not form, or form slowly
and inefficiently. What, then, is the role of the TM do- 
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main? Through a thorough and careful series of experi-
ments, Armstrong et al. (2000) show that the TM domain
must completely span the lipid bilayer for fusion to occur.
If it does not, only hemifusion takes place. Whereas the
reason for this is not clear, it is possible that the TM do-
main must be firmly anchored in the membrane to apply
enough tension to the hemifusion diaphragm to promote
pore formation. Since the transition to the six-helix bundle
is coincident with membrane fusion, the TM domain, and
perhaps also the fusion peptide, must be tightly mem-
brane-associated to bring the viral and cellular membranes
into close proximity. Thus, the TM domain plays an im-
portant role in the fusion process. It will be interesting to
determine if the presence of a GPI-anchor or a short TM
domain prevents complete formation of the six-helix bun-
dle, or if formation of the six-helix bundle results in extrac-
tion of membrane domains that do not span the lipid bi-
layer, thereby preventing lipid mixing. In this regard, it is
notable that some mutations in the fusion peptide allow
only hemifusion to occur (Qiao et al., 1999).
While wonderful creatures to study, it must be admitted
that viruses are frequently guilty of plagiarism, stealing
good ideas from unsuspecting cells for their own nefarious
purposes. It is perhaps not surprising then that cellular and
viral fusion machines share some features in common. To
cause fusion, v-SNAREs that are anchored in a vesicle
membrane and t-SNAREs that are anchored in the target
membrane associate and form a four-helix bundle that is
thought to force the two membranes together. The pa-
per by Grote et al. (2000) shows that substitution of the
t-SNARE membrane domains with a gernylgernylation
signal inhibits exocytosis after vesicle docking. In fact, this
 
lipid modification proved to be a dominant inhibitor of
membrane fusion, consistent with a need for cooperative
interactions between multiple SNARE complexes. Fusion
could be rescued by addition of lysophosphatidylcholine, a
cone-shaped lipid that induces membrane curvature. Al-
tering membrane curvature has been shown to induce full
membrane fusion by GPI-HA, so perhaps the activity of
the lipid-anchored t-SNARE is blocked at the hemifusion
stage. Thus, much like GPI-anchored HA, the presence of
a lipid anchor that fails to span the membrane is not com-
patible with membrane fusion. The papers by Armstrong
et al. (2000), Grote et al. (2000), and others (Qiao et al.,
1999; McNew et al., 2000) indicate that for membrane fu-
sion to occur, fusion proteins must have both feet firmly
planted in, and not just on, the ground.
As the details of the virus entry process have been re-
vealed, it is apparent that structural intermediates of the
fusion process represent attractive drug targets. The HIV-1
Env protein is well armored to resist humoral immunity:
nearly half of its mass is contributed by N-linked carbohy-
drate chains that shield antibody epitopes, and surface ac-
cessible regions of the protein tend to consist of variable
regions. This makes the development of broadly neutraliz-
ing antibodies a challenge. The Env protein does contain
highly conserved, functionally important domains since all
Env proteins bind CD4 and a coreceptor, then cause mem-
brane fusion. Unfortunately, these structures either are
not, or may not be, accessible to antibodies until the recep-
tors have been engaged. Structural intermediates of the fu-
sion process may result in the exposure of conserved do-
mains that could be potential drug or vaccine targets.
However, even here, there may be little time for an anti-
Figure 2. Model for HA-induced membrane fusion. The HA trimer consists of both HA1 (not shown for clarity) and HA2 subunits.
The fusion peptides are hidden in the native conformation, being tucked into the trimer interface. Upon acid activation, the fusion pep-
tides are exposed and directed towards the target membrane by a loop to helix transition (blue), thus extending the triple-stranded
coiled-coil (1). Insertion of the fusion peptide into the target membrane (2) links the viral and target membranes. Lateral aggregation of
several HA trimers (3) is likely needed for a fusion pore to form. Tilting of the HA trimers may be accomplished by folding of the base
of triple stranded coiled-coil upon itself, forming a six-helix bundle, as has been seen for other viral fusion proteins (4). This may bring
the membranes in close enough proximity such that hemifusion occurs (5). If the HA trimer is GPI-anchored or if the transmembrane
domain is not of sufficient length to span the bilayer, the fusion process does not extend past this point. However, if the TM domain is
well anchored in the viral membrane, fusion occurs, and, judging by the work by Melikyan et al. (2000, this issue) may be coincident
with the completion of the six-helix bundle that brings the TM domain and fusion peptides into close proximity (6).  
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body to intervene or only a limited physical space in which
it can do so, given the steric constraints of a forming fusion
complex. The work by Melikyan et al. (2000) indicates that
binding of CD4 to trimeric Env at room temperature is
sufficient to not only expose the conserved coreceptor
binding site in gp120, but also to render Env susceptible to
fusion-inhibiting agents such as T20. The use of coreceptor
antagonists may further slow the fusion process by reduc-
ing the density of functional coreceptors. This could pro-
long the exposure of conserved, critically important do-
mains such as those on the surface of the triple stranded
coiled-coil. Combination chemotherapy with different
classes of entry inhibitors may therefore result in synergis-
tic, and not just additive, inhibition of virus infection.
The study by Melikyan et al. (2000) also helps explain
why antibodies to the six-helix bundle are nonneutralizing,
yet highly prevalent. One terminology point that needs
clarifying as a result of this study is that the six-helix bundle
form of gp41 is often referred to as the fusogenic or fusion-
competent form of gp41, and nonneutralizing antibodies to
this fusion-competent structure have been described
(Gorny and Zolla-Pazner, 2000). We now know this no-
menclature to be incorrect; as outlined above, it is the tran-
sition to the six-helix form that drives fusion, not the six-
helix form itself. Thus, antibodies to the six-helix form are
nonneutralizing because their epitopes are formed coinci-
dent with membrane fusion, not before it, so they cannot
intervene to stop fusion occurring (i.e., to neutralize the in-
fectivity of the virus). These antibodies are prevalent be-
cause the six-helix structure is an antigen that is both stable
and accessible on the surface of virions and virus-infected
cells. A more accurate terminology for the six-helix form of
gp41 is the postfusion form or, colloquially, dead spikes.
Antibodies to such dead spikes are common in the sera
of HIV-1-infected humans; the postfusion form of gp41 is
immunodominant, but unfortunately irrelevant to an ef-
fective virus-neutralizing antibody response (Parren et al.,
1999). Thus, some stable Env structures, including mono-
meric gp120 released from the cell surface, function in part
as immunological decoys. These abundant Env-specific
antibodies fail to react with the native, fusion-competent
trimeric protein, or do so poorly. However, one human
anti-gp41 antibody, 2F5, is known to be able to prevent
membrane fusion subsequently to virus–cell attachment
(Ugolini et al., 1997). It will be important to use the exper-
imental systems outlined by Melikyan et al. (2000) to try to
understand at what stage of the fusion process this anti-
body successfully intervenes. Overall, a goal of vaccine de-
velopment is to minimize the generation of antibodies to
the immunological decoy forms of Env while maximizing
the presentation of Env antigens in which the structures
important for driving, or actively involved in, the fusion
process are exposed. Greater appreciation of the condi-
tions under which Env undergoes its conformational gym-
nastics, and the requirements for membrane fusion, can
only help in identifying targets of opportunity for the use
of small molecule inhibitors and in the generation of neu-
tralizing antibodies.
 
The drawing of Fig. 2 was kindly provided by Jennifer Gruenke and Judy
M. White. More information on the model can be found on Judy White’s
laboratory web site.
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